Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). - De Grève J; Van Meerbeeck J; Vansteenkiste JF; Decoster L; Meert AP; Vuylsteke P; Focan C; Canon JL; Humblet Y; Berchem G; Colinet B; Galdermans D; et al. (PloS one, 2016)